<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27825791</identifier>
<setSpec>1885-1398</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Tornero-Molina, Jesús</dc:author>
<dc:author>Blanco-García, Francisco Javier</dc:author>
<dc:author>Blanco-Alonso, Ricardo</dc:author>
<dc:author>Fernández-Nebro, Antonio</dc:author>
<dc:author>Martín-Martínez, María Auxiliadora</dc:author>
<dc:author>García-Vicuña, Rosario</dc:author>
<dc:author>Gonzalez-Crespo, María Rosa</dc:author>
<dc:author>Marsal-Barril, Sara</dc:author>
<dc:description xml:lang="en">To establish a set of recommendations for the management of patients diagnosed with rheumatoid arthritis (RA) who cannot be treated with methotrexate (MTX) due to contraindications, drug toxicity or lack of adherence, and to establish therapeutic strategies more effective and safer in these RA patients. A qualitative analysis of the scientific evidence available to June 2015. The 2-round Delphi technique of consensus was used to collect and establish expert opinion based on the participants' clinical experience when only low quality evidence was available. A total of eighteen recommendations were developed for the management of this patient profile. Fourteen of these recommendations were related to drug safety aspects. Recommendations on contraindication and toxicity of MTX have been updated. The experts recommend the use of biological monotherapy, a preferred treatment option, in patients whose profiles reveal a contraindication, intolerance or circumstances that prevent us against the use of MTX. There is some high-quality scientific evidence that supports contraindication and establishes certain conditions of MTX use in RA patients with specific clinical profiles.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Medication adherence</dc:subject>
<dc:subject>Adherencia farmacológica</dc:subject>
<dc:subject>Artritis reumatoide</dc:subject>
<dc:subject>Metotrexato</dc:subject>
<dc:subject>Anti-rheumatic agents</dc:subject>
<dc:subject>Contraindicación</dc:subject>
<dc:subject>Toxicity</dc:subject>
<dc:subject>Rheumatoid arthritis</dc:subject>
<dc:subject>Toxicidad</dc:subject>
<dc:subject>Fármacos antirreumáticos</dc:subject>
<dc:subject>Methotrexate</dc:subject>
<dc:subject>Contraindications</dc:subject>
<dc:date>2017 May - Jun </dc:date>
<dc:title xml:lang="es">Documento de Recomendaciones de la Sociedad Española de Reumatología para el manejo clínico del paciente con artritis reumatoide que no puede utilizar metotrexato.</dc:title>
<dc:title xml:lang="en">Recommendations by the Spanish Society of Rheumatology for the management of patients diagnosed with rheumatoid arthritis who cannot be treated with methotrexate.</dc:title>
<dc:publisher>Reumatologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
